QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.

Press

20May 2021

Research Analyst Heloisa Conesa joins Quantify

On Monday we welcomed Heloisa Ricci Conesa to the team as our newest Research Analyst!

Heloisa is a pharmacist from Brazil with 10-years of professional experience in pharmacovigilance. She has worked in national, regional and global settings in the pharmaceutical industry and a WHO Collaborating Centre. Heloisa just finished her Master Degree in Health Economics, Policy and Management at Karolinska Institutet and is now ready for her next adventure at Quantify.

Thank […]

17May 2021

We are part of the fight against severe asthma!

Quantify plays a key role in the NORDSTAR collaboration alongside our academic and industry partners, where we build and analyze the world’s most extensive asthma dataset to improve the lives of asthma patients. Gustav Segerberg and Hanna Fues Wahl play a central role in this work and our CEO Kirk Geale sits on the Steering Committee.

NORDSTAR is a unique multi-country collaboration between Nordic clinical asthma experts, […]

3May 2021

Analyses From BISCUITS, a Large Nordic Observational Cohort Study

The poster “Healthcare Resource Use and Treatment Patterns in Patients With Difficult-to-Treat Osteoarthritis in Sweden: Analyses From ‘BISCUITS’, a Large Nordic Observational Cohort Study”, co-authored by Quantify’s Johan Liseth Hansen, describes the treatment patterns for NSAIDs and opioids in Swedish patients with a diagnosis of #osteoartritis (OA), including subgroups of patients defined as difficult-to-treat.
The findings, combined with other learnings from the BISCUITS study, create […]

28Apr 2021

Abstract co-authored by Quantify’s E. Toresson Grip presented at Heart Failure 2021 Online Congress

An abstract co-authored by Quantify’s Emilie Toresson Grip, has been accepted for oral presentation at the European Society of Cardiology Heart Failure 2021 Online Congress in June. For this abstract, called “Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk of cardiovascular and renal disease among type 2 diabetes patients in routine care in Europe and Israel: EMPRISE study results”, the Quantify […]